Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin.

Ruggiero CF, Malpicci D, Fattore L, Madonna G, Vanella V, Mallardo D, Liguoro D, Salvati V, Capone M, Bedogni B, Ascierto PA, Mancini R, Ciliberto G.

Cancers (Basel). 2019 Sep 25;11(10). pii: E1425. doi: 10.3390/cancers11101425.

2.

The membrane tethered matrix metalloproteinase MT1-MMP triggers an outside-in DNA damage response that impacts chemo- and radiotherapy responses of breast cancer.

Thakur V, Zhang K, Savadelis A, Zmina P, Aguila B, Welford SM, Abdul-Karim F, Bonk KW, Keri RA, Bedogni B.

Cancer Lett. 2019 Feb 28;443:115-124. doi: 10.1016/j.canlet.2018.11.031. Epub 2018 Nov 29.

PMID:
30502358
3.

Inhibiting Notch1 enhances immunotherapy efficacy in melanoma by preventing Notch1 dependent immune suppressive properties.

Qiu H, Zmina PM, Huang AY, Askew D, Bedogni B.

Cancer Lett. 2018 Oct 10;434:144-151. doi: 10.1016/j.canlet.2018.07.024. Epub 2018 Jul 21.

PMID:
30036609
4.

The natural compound fucoidan from New Zealand Undaria pinnatifida synergizes with the ERBB inhibitor lapatinib enhancing melanoma growth inhibition.

Thakur V, Lu J, Roscilli G, Aurisicchio L, Cappelletti M, Pavoni E, White WL, Bedogni B.

Oncotarget. 2017 Mar 14;8(11):17887-17896. doi: 10.18632/oncotarget.14437.

5.

Cellular Prion Protein Mediates Pancreatic Cancer Cell Survival and Invasion through Association with and Enhanced Signaling of Notch1.

Wang Y, Yu S, Huang D, Cui M, Hu H, Zhang L, Wang W, Parameswaran N, Jackson M, Osborne B, Bedogni B, Li C, Sy MS, Xin W, Zhou L.

Am J Pathol. 2016 Nov;186(11):2945-2956. doi: 10.1016/j.ajpath.2016.07.010. Epub 2016 Sep 14. Erratum in: Am J Pathol. 2017 Mar;187(3):689.

6.

The thiirane-based selective MT1-MMP/MMP2 inhibitor ND-322 reduces melanoma tumor growth and delays metastatic dissemination.

Marusak C, Bayles I, Ma J, Gooyit M, Gao M, Chang M, Bedogni B.

Pharmacol Res. 2016 Nov;113(Pt A):515-520. doi: 10.1016/j.phrs.2016.09.033. Epub 2016 Sep 26.

7.

The membrane tethered matrix metalloproteinase MT1-MMP at the forefront of melanoma cell invasion and metastasis.

Thakur V, Bedogni B.

Pharmacol Res. 2016 Sep;111:17-22. doi: 10.1016/j.phrs.2016.05.019. Epub 2016 May 21. Review.

PMID:
27221755
8.

Synchronized Targeting of Notch and ERBB Signaling Suppresses Melanoma Tumor Growth through Inhibition of Notch1 and ERBB3.

Zhang K, Wong P, Salvaggio C, Salhi A, Osman I, Bedogni B.

J Invest Dermatol. 2016 Feb;136(2):464-472. doi: 10.1016/j.jid.2015.11.006. Epub 2015 Nov 18.

9.

MT1-MMP dependent repression of the tumor suppressor SPRY4 contributes to MT1-MMP driven melanoma cell motility.

Shaverdashvili K, Zhang K, Osman I, Honda K, Jobava R, Bedogni B.

Oncotarget. 2015 Oct 20;6(32):33512-22. doi: 10.18632/oncotarget.5258.

10.

Notch1 Autoactivation via Transcriptional Regulation of Furin, Which Sustains Notch1 Signaling by Processing Notch1-Activating Proteases ADAM10 and Membrane Type 1 Matrix Metalloproteinase.

Qiu H, Tang X, Ma J, Shaverdashvili K, Zhang K, Bedogni B.

Mol Cell Biol. 2015 Nov;35(21):3622-32. doi: 10.1128/MCB.00116-15. Epub 2015 Aug 17.

11.

Noncanonical activation of Notch1 protein by membrane type 1 matrix metalloproteinase (MT1-MMP) controls melanoma cell proliferation.

Ma J, Tang X, Wong P, Jacobs B, Borden EC, Bedogni B.

J Biol Chem. 2014 Mar 21;289(12):8442-9. doi: 10.1074/jbc.M113.516039. Epub 2014 Feb 3.

12.

MT1-MMP modulates melanoma cell dissemination and metastasis through activation of MMP2 and RAC1.

Shaverdashvili K, Wong P, Ma J, Zhang K, Osman I, Bedogni B.

Pigment Cell Melanoma Res. 2014 Mar;27(2):287-96. doi: 10.1111/pcmr.12201. Epub 2014 Jan 6.

PMID:
24387669
13.

The apoptosis repressor with a CARD domain (ARC) gene is a direct hypoxia-inducible factor 1 target gene and promotes survival and proliferation of VHL-deficient renal cancer cells.

Razorenova OV, Castellini L, Colavitti R, Edgington LE, Nicolau M, Huang X, Bedogni B, Mills EM, Bogyo M, Giaccia AJ.

Mol Cell Biol. 2014 Feb;34(4):739-51. doi: 10.1128/MCB.00644-12. Epub 2013 Dec 16.

14.

Notch signaling in melanoma: interacting pathways and stromal influences that enhance Notch targeting.

Bedogni B.

Pigment Cell Melanoma Res. 2014 Mar;27(2):162-8. doi: 10.1111/pcmr.12194. Epub 2013 Dec 16. Review.

PMID:
24330305
15.

An ERBB3/ERBB2 oncogenic unit plays a key role in NRG1 signaling and melanoma cell growth and survival.

Zhang K, Wong P, Duan J, Jacobs B, Borden EC, Bedogni B.

Pigment Cell Melanoma Res. 2013 May;26(3):408-14. doi: 10.1111/pcmr.12089. Epub 2013 Apr 2. Erratum in: Pigment Cell Melanoma Res. 2013 Jul;26(4):601.

PMID:
23480537
16.

CTGF is a therapeutic target for metastatic melanoma.

Finger EC, Cheng CF, Williams TR, Rankin EB, Bedogni B, Tachiki L, Spong S, Giaccia AJ, Powell MB.

Oncogene. 2014 Feb 27;33(9):1093-100. doi: 10.1038/onc.2013.47. Epub 2013 Feb 25.

17.

A Notch1-neuregulin1 autocrine signaling loop contributes to melanoma growth.

Zhang K, Wong P, Zhang L, Jacobs B, Borden EC, Aster JC, Bedogni B.

Oncogene. 2012 Oct 25;31(43):4609-18. doi: 10.1038/onc.2011.606. Epub 2012 Jan 16.

18.

VHL loss in renal cell carcinoma leads to up-regulation of CUB domain-containing protein 1 to stimulate PKC{delta}-driven migration.

Razorenova OV, Finger EC, Colavitti R, Chernikova SB, Boiko AD, Chan CK, Krieg A, Bedogni B, LaGory E, Weissman IL, Broome-Powell M, Giaccia AJ.

Proc Natl Acad Sci U S A. 2011 Feb 1;108(5):1931-6. doi: 10.1073/pnas.1011777108. Epub 2011 Jan 13.

19.

Unique transforming properties of Notch1 in human melanocytes.

Bedogni B, Powell MB.

Pigment Cell Melanoma Res. 2009 Dec;22(6):702-3. doi: 10.1111/j.1755-148X.2009.00625.x. Epub 2009 Aug 26. No abstract available.

PMID:
19708913
20.

Hypoxia, melanocytes and melanoma - survival and tumor development in the permissive microenvironment of the skin.

Bedogni B, Powell MB.

Pigment Cell Melanoma Res. 2009 Apr;22(2):166-74. doi: 10.1111/j.1755-148X.2009.00553.x. Epub 2009 Feb 13. Review.

21.

Notch1 is an effector of Akt and hypoxia in melanoma development.

Bedogni B, Warneke JA, Nickoloff BJ, Giaccia AJ, Powell MB.

J Clin Invest. 2008 Nov;118(11):3660-70. doi: 10.1172/JCI36157. Epub 2008 Oct 16.

22.

Targeting integrins and PI3K/Akt-mediated signal transduction pathways enhances radiation-induced anti-angiogenesis.

Ning S, Chen Z, Dirks A, Husbeck B, Hsu M, Bedogni B, O'Neill M, Powell MB, Knox SJ.

Radiat Res. 2007 Jul;168(1):125-33.

PMID:
17722999
23.
24.

HIF1alpha delays premature senescence through the activation of MIF.

Welford SM, Bedogni B, Gradin K, Poellinger L, Broome Powell M, Giaccia AJ.

Genes Dev. 2006 Dec 15;20(24):3366-71. Epub 2006 Dec 1.

25.

Skin hypoxia: a promoting environmental factor in melanomagenesis.

Bedogni B, Powell MB.

Cell Cycle. 2006 Jun;5(12):1258-61. Epub 2006 Jun 15.

PMID:
16760649
26.

The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation.

Bedogni B, Welford SM, Cassarino DS, Nickoloff BJ, Giaccia AJ, Powell MB.

Cancer Cell. 2005 Dec;8(6):443-54.

27.

Protective role of MnSOD and redox regulation of neuronal cell survival.

Galeotti T, Pani G, Capone C, Bedogni B, Borrello S, Mancuso C, Eboli ML.

Biomed Pharmacother. 2005 May;59(4):197-203. Epub 2005 Mar 17.

PMID:
15862715
28.

Mitochondrial superoxide dismutase: a promising target for new anticancer therapies.

Pani G, Colavitti R, Bedogni B, Fusco S, Ferraro D, Borrello S, Galeotti T.

Curr Med Chem. 2004 May;11(10):1299-308. Review.

PMID:
15134521
30.

Redox regulation of cAMP-responsive element-binding protein and induction of manganous superoxide dismutase in nerve growth factor-dependent cell survival.

Bedogni B, Pani G, Colavitti R, Riccio A, Borrello S, Murphy M, Smith R, Eboli ML, Galeotti T.

J Biol Chem. 2003 May 9;278(19):16510-9. Epub 2003 Feb 27.

31.

Determination of intracellular reactive oxygen species as function of cell density.

Pani G, Colavitti R, Bedogni B, Anzevino R, Borrello S, Galeotti T.

Methods Enzymol. 2002;352:91-100. No abstract available.

PMID:
12125380
32.

Cell compartmentalization in redox signaling.

Pani G, Bedogni B, Colavitti R, Anzevino R, Borrello S, Galeotti T.

IUBMB Life. 2001 Jul;52(1-2):7-16. Review.

33.

Reactive oxygen species as downstream mediators of angiogenic signaling by vascular endothelial growth factor receptor-2/KDR.

Colavitti R, Pani G, Bedogni B, Anzevino R, Borrello S, Waltenberger J, Galeotti T.

J Biol Chem. 2002 Feb 1;277(5):3101-8. Epub 2001 Nov 21.

34.

A redox signaling mechanism for density-dependent inhibition of cell growth.

Pani G, Colavitti R, Bedogni B, Anzevino R, Borrello S, Galeotti T.

J Biol Chem. 2000 Dec 8;275(49):38891-9.

35.

Deregulated manganese superoxide dismutase expression and resistance to oxidative injury in p53-deficient cells.

Pani G, Bedogni B, Anzevino R, Colavitti R, Palazzotti B, Borrello S, Galeotti T.

Cancer Res. 2000 Aug 15;60(16):4654-60.

36.

Increased growth capacity of cervical-carcinoma cells over-expressing manganous superoxide dismutase.

Palazzotti B, Pani G, Colavitti R, De Leo ME, Bedogni B, Borrello S, Galeotti T.

Int J Cancer. 1999 Jul 2;82(1):145-50.

Supplemental Content

Loading ...
Support Center